HCA Healthcare Analysts Slash Their Forecasts After Q2 Results

HCA Healthcare Inc. (NYSE: HCA ) on Friday posted upbeat second-quarter earnings.

The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion.

The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.

HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70.

The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.

HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

Barclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.

Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.

Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.

Oppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.

Truist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.

Considering buying HCA stock? Here’s what analysts think: Photo via Shutterstock